Cyprotex Discovery Receives French Research Tax Credit Accreditation

MACCLESFIELD, England, April 21, 2010 - Cyprotex (AIM:CRX), the drug discovery technology and
information company, is pleased to announce that it has received French
research tax credit approval for years 2009 through to 2011.

The French Ministry of Research (Ministère de l'Enseignement
Supérieur et de la Recherche) has granted the French R&D tax credit ("Crédit
d'Impôt Recherche", CIR) accreditation to Cyprotex as of March 2010. This
initiative allows eligible French pharmaceutical, biotech and agricultural
companies subject to corporate tax in France, the ability to claim
significant tax relief on costs generated in R&D requirements that are
outsourced to Cyprotex Discovery.

Dr Anthony Baxter, Cyprotex's Chief Executive Officer,
comments: 'We are delighted to receive this recognition and approval from the
French Ministry of Research which will provide greater opportunities to
support our current client base and allow for improved collaborations with
future French clients.'

Additional information on the French research tax credit system is
available from the Ministère de l'Enseignement Supérieur et de la Recherche
site - www.enseignementsup-recherche.gouv.fr/

    For further information:

    Cyprotex PLC
    Dr. Anthony Baxter, Chief Executive Officer
    Tel: +44-1625-505-100
    a.baxter@cyprotex.com
    www.cyprotex.com

    Execution Noble & Company Limited
    John Llewellyn-Lloyd
    Sam Reynolds
    Tel:+44(0)20-7456-9191

    Public Relations
    Financial Dynamics
    Ben Brewerton
    Ben Atwell
    Mo Noonan
    Tel: +44(0)20-7831-3113

For further information: Cyprotex PLC, Dr. Anthony Baxter, Chief Executive Officer, Tel: +44-1625-505-100, a.baxter at cyprotex.com, www.cyprotex.com; Execution Noble & Company Limited, John Llewellyn-Lloyd, Sam Reynolds, Tel:+44(0)20-7456-9191; Public Relations, Financial Dynamics, Ben Brewerton, Ben Atwell, Mo Noonan, Tel: +44(0)20-7831-3113